Seattle Genetics begins trial of vadastuximab talirine combination therapy in MDS patients
US-based Seattle Genetics has started a Phase I/II clinical trial of vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza), a hypomethylating agent (HMA), in patients with previously untreated myelodysplastic syndrome (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - February 23, 2016 Category: Pharmaceuticals Source Type: news
Azacitidine-Induced Cryptogenic Organizing PneumoniaAzacitidine-Induced Cryptogenic Organizing Pneumonia
This case report highlights an important, potentially treatable and rare side effect of azacitidine, a hypomethylating agent used in the treatment of myelodysplastic syndrome. Journal of Medical Case Reports (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 18, 2016 Category: Intensive Care Tags: Hematology-Oncology Journal Article Source Type: news
Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)
First Phase 3 Data From Placebo-Controlled Study With an Erythropoiesis-Stimulating Agent (ESA) in Anemic Patients With MDS
Study Met Primary Endpoint and Key Secondary Endpoint of Erythroid Response
THOUSAND OAKS, Calif., Feb. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the randomized, double-blind, placebo-controlled Phase 3 Aranesp® (darbepoetin alfa) ARCADE trial met its primary endpoint of reducing the incidence of red blood cell transfusions in anemic patients with low and intermediate-1 risk MDS at the end of the blinded 25-week study period. Aranesp also significantly improved erythro...
Source: Amgen News Release - February 15, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Summary Information for: PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Labeling, Approval Order, and Summary of Safety and Effectiveness for PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) (H140005). (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - January 14, 2016 Category: Medical Equipment Source Type: news
McMaster researchers reveal predictive staircase to leukemia
(McMaster University) In the paper published today by the scientific journal Cancer Cell, the researchers detail how they have been able to fingerprint myelodysplastic syndromes, a state for blood cells that turns into acute myeloid leukemia cancer in approximately 30 percent of patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 11, 2016 Category: Cancer & Oncology Source Type: news
Study shows age doesn't affect survival outcomes in patients with MDS who receive a HCT
(Padilla Speer Beardsley) Prospective study, presented at the 57th Annual Meeting of the American Society of Hematology, shows age doesn't affect survival outcomes in patients with myelodysplastic syndrome (MDS) who receive a hematopoietic cell transplant. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 6, 2015 Category: Global & Universal Source Type: news
Temple & Fox Chase Cancer Center testing drug for cancer & bone marrow disorders
(Temple University Health System) Temple University Hospital and Fox Chase Cancer Center are the only two sites in Philadelphia that participated in an international phase I, randomized clinical trial which tested the drug guadecitabine (SGI-110) in Myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML). MDS are a group of bone marrow disorders in which the bone marrow doesn't produce enough healthy blood cells. AML is a cancer of the blood and bone marrow. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 18, 2015 Category: Cancer & Oncology Source Type: news
Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research and Development Expert, To Board of Directors
BEVERLY HILLS, Calif., Aug. 11, 2015 -- (Healthcare Sales & Marketing Network) -- Rich Pharmaceuticals, Inc. (RCHAE) ("Rich Pharmaceuticals" or the "Company") announced today that Dr. Richard A. Salvador will be joining the corporate b... Biopharmaceuticals, Oncology, PersonnelRich Pharmaceuticals, Acute Myelocytic Leukemia, Myelodysplastic Syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 11, 2015 Category: Pharmaceuticals Source Type: news
Case study reveals therapy to reduce sarcoidosis symptoms in 5q-myelodysplastic syndrome
(American College of Chest Physicians) A case study published in the August issue of the journal CHEST found lenalidomide treatments may have an immediate effect in the treatment of sarcoidosis-related symptoms. Sarcoidosis, a disease that involves abnormal collections of inflammatory cells that can form nodules in various organs, can affect individuals from all racial and age groups. To date, no optimal therapies have been effective in managing this condition. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 4, 2015 Category: Global & Universal Source Type: news
Trial could impact older myelodysplastic syndrome population's access to bone marrow transplants
An America-wide clinical trial analyzes outcomes after two common treatments: bone marrow transplant and chemotherapy. The results could lead to wider access to transplants, researchers say. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 23, 2015 Category: Science Source Type: news
BBC bosses launch Save Our Sue bid for Sue Lloyd-Roberts who has cancer
Sue Lloyd-Roberts, 62, says it is ‘a race against time’ to have a cell transplant after she was diagnosed with blood disorder myelodysplastic syndrome that had developed into leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - June 18, 2015 Category: Consumer Health News Source Type: news
Study may suggest new strategies for myelodysplastic syndromes treatment
(University of Texas M. D. Anderson Cancer Center) A study revealing fresh insight about chromosome 'tails' called telomeres may provide scientists with a new way to look at developing treatments or even preventing a group of blood cell disorders known as myelodysplastic syndromes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 11, 2015 Category: Cancer & Oncology Source Type: news
Study May Suggest New Strategies for Myelodysplastic Syndromes Treatment
A study revealing fresh insight about chromosome "tails" called telomeres may provide scientists with a new way to look at developing treatments or even preventing a group of blood cell disorders known as myelodysplastic syndromes (MDS). (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - May 11, 2015 Category: Cancer & Oncology Source Type: news
